Divya Samineni

1.5k total citations
27 papers, 627 citations indexed

About

Divya Samineni is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Hematology. According to data from OpenAlex, Divya Samineni has authored 27 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Hematology. Recurrent topics in Divya Samineni's work include Monoclonal and Polyclonal Antibodies Research (12 papers), HER2/EGFR in Cancer Research (11 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Divya Samineni is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), HER2/EGFR in Cancer Research (11 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Divya Samineni collaborates with scholars based in United States, Australia and Egypt. Divya Samineni's co-authors include Chunze Li, Dan Lu, Sandhya Girish, Carl J. Fichtenbaum, Dale Miles, Pankaj B. Desai, Bernard M. Fine, Matts Kågedal, Larry Sallans and Daniel Maslyar and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Advanced Drug Delivery Reviews.

In The Last Decade

Divya Samineni

27 papers receiving 587 citations

Peers

Countries citing papers authored by Divya Samineni

Since Specialization

Citations

This map shows the geographic impact of Divya Samineni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Divya Samineni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Divya Samineni more than expected).

Fields of papers citing papers by Divya Samineni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Divya Samineni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Divya Samineni. The network helps show where Divya Samineni may publish in the future.

Co-authorship network of co-authors of Divya Samineni

This figure shows the co-authorship network connecting the top 25 collaborators of Divya Samineni. A scholar is included among the top collaborators of Divya Samineni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Divya Samineni. Divya Samineni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings 2024 ·Advanced Drug Delivery Reviews ·Michael Z. Liao, Dan Lu, Tong Lu, Leonid Gibiansky, Rong Deng, Divya Samineni, Randall Dere, (unknown), Jamie Hirata, Ben‐Quan Shen, Donglu Zhang, Dongwei Li, Chunze Li, Dale Miles	2
2	CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent. 2023 ·Journal of Clinical Oncology ·Shaji Kumar, Carlos Bachier, Michèle Cavo, Paolo Corradini, Michel Delforge, Wojciech Janowski, Alexander M. Lesokhin, Roberto Mina, Laura París, Laura Rosiñol, Hang Quach, Grant R. Goodman, Rin Nakamura, Divya Samineni, Vallari Shah, (unknown), Jesús G. Berdeja	26
3	Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study 2022 ·Clinical Cancer Research ·Alex F. Herrera, Manish R. Patel, John M. Burke, Ranjana H. Advani, Bruce D. Cheson, Jeff P. Sharman, Elicia Penuel, Andrew G. Polson, Chen Di Liao, Chunze Li, (unknown), Anjali Vaze, Divya Samineni, Rebecca Elstrom, James Cooper, Catherine Diefenbach	21
4	Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet 2022 ·Clinical Drug Investigation ·Mohamed Badawi, Xin Chen, Patrick Marroum, Ahmed A. Suleiman, Sven Mensing, (unknown), (unknown), Tammy L. Palenski, Divya Samineni, David Hoffman, Rajeev Menon, Ahmed Hamed Salem	6
5	Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial 2022 ·Advances in Therapy ·Divya Samineni, Leonid Gibiansky, Bei Wang, Shweta Vadhavkar, (unknown), Maneesh Tandon, Arijit Sinha, Othman Al‐Sawaf, Kirsten Fischer, Michael Hallek, Ahmed Hamed Salem, Chunze Li, Dale Miles	7
6	CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma. 2022 ·Journal of Clinical Oncology ·Ravi Vij, (unknown), Suzanne Trudel, Alice Chinghsuan Chang, Jiangeng Huang, Divya Samineni, Teiko Sumiyoshi, Jennifer J. Tsai, Tiffany Wong, Simon J. Harrison	6
7	CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma. 2022 ·Journal of Clinical Oncology ·Sosana Delimpasi, Hang Quach, Michèle Cavo, P. Joy Ho, Cindy Lee, Armando Santoro, Rik Schots, Philip Vlummens, Dok Hyun Yoon, Sung‐Soo Yoon, Cédric Dos Santos, Divya Samineni, Jiangeng Huang, (unknown), (unknown), (unknown), Meletios Α. Dimopoulos	1
8	Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma 2021 ·Advances in Therapy ·Divya Samineni, Weize Huang, Leonid Gibiansky, Hao Ding, (unknown), Chunze Li, Arijit Sinha, (unknown), Kathryn Humphrey, Alexandra Bazeos, Ahmed Hamed Salem, Dale Miles	9
9	Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma 2020 ·Blood ·Adam D. Cohen, Simon J. Harrison, Amrita Krishnan, Rafaël Fonseca, Peter A. Forsberg, Andrew Spencer, Jesús G. Berdeja, Jacob P. Laubach, (unknown), Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M. Fine, Suzanne Trudel	65
10	Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer 2020 ·Gynecologic Oncology ·Kathleen N. Moore, Michael J. Birrer, (unknown), Yulei Wang, YounJeong Choi, Stephanie Royer‐Joo, Vanessa Lemahieu, (unknown), Julie Cordova, Divya Samineni, (unknown), Anjali Vaze, Daniel Maslyar, Eric W. Humke, Erika Hamilton, Joyce F. Liu	26
11	Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies 2019 ·mAbs ·Chunze Li, Cindy Zhang, Zao Li, Divya Samineni, Dan Lu, Bei Wang, (unknown), (unknown), Priya Agarwal, Bernard M. Fine, Sandhya Girish	41
12	Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates 2019 ·CPT Pharmacometrics & Systems Pharmacology ·Matts Kågedal, Divya Samineni, William R. Gillespie, Dan Lu, Bernard M. Fine, Sandhya Girish, Chunze Li, Jin Y. Jin	12
13	Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates 2017 ·Journal of Pharmacokinetics and Pharmacodynamics ·Matts Kågedal, Leonid Gibiansky, Jian Xu, Xin Wang, Divya Samineni, (unknown), Dan Lu, Priya Agarwal, Bei Wang, Ola M. Saad, Neelima Koppada, Bernard M. Fine, Jin Y. Jin, Sandhya Girish, Chunze Li	9
14	A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma 2016 ·Respiratory Research ·Jeffrey M. Harris, Romeo Maciuca, Mary S. Bradley, Christopher R. Cabanski, Heleen Scheerens, Jeremy J. Lim, Fang Cai, (unknown), X. Charlene Liao, Divya Samineni, Rui Zhu, (unknown), Weily Soong, Joseph D. Diaz, (unknown), (unknown), Dimo Dimov, Ioana Agache, Steven G. Kelsen	73
15	Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics 2016 ·The AAPS Journal ·Siddharth Sukumaran, Crystal Zhang, Douglas D. Leipold, Ola M. Saad, Keyang Xu, Kapil Gadkar, Divya Samineni, Bei Wang, (unknown), Montserrat Carrasco‐Triguero, Bonnee Rubinfeld, Paul J. Fielder, Kedan Lin, Saroja Ramanujan	19
16	Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates 2014 ·Clinical Pharmacokinetics ·Yuan Chen, Divya Samineni, Sophie Mukadam, Harvey Wong, Ben‐Quan Shen, Dan Lu, Sandhya Girish, Cornelis E. C. A. Hop, Jin Y. Jin, Chunze Li	32
17	Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC‐MS/MS cocktail assays and RT‐PCR 2012 ·Biopharmaceutics & Drug Disposition ·Li Liu, Ganesh Mugundu, Brian J. Kirby, Divya Samineni, Pankaj B. Desai, Jashvant D. Unadkat	13
18	Brain distribution and elimination of recombinant human TIMP-1 after cerebral ischemia and reperfusion in rats 2011 ·Neurological Research ·(unknown), Jinsong Hao, Divya Samineni, Joseph F. Clark, Gail J. Pyne‐Geithman, Joseph P. Broderick, Aigang Lu	12
19	Steady‐State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid‐Lowering Agent Rosuvastatin 2011 ·The Journal of Clinical Pharmacology ·Divya Samineni, Pankaj B. Desai, Larry Sallans, Carl J. Fichtenbaum	33
20	Fenofibrate in the treatment of dyslipidemia associated with HIV infection 2010 ·Expert Opinion on Drug Metabolism & Toxicology ·Divya Samineni, Carl J. Fichtenbaum	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact